Antidepressants, suicidality and rebound effect: evidence of similitude?

Homeopathy

Volumn 98, Issue 2, 2009, Pages 114-121

  Teixeira, Marcus Zulian ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

antidepressant; homeopathic medicines; paradoxical reaction; rebound effect; secondary effect; similitude; suicide; withdrawal syndrome

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; OLANZAPINE; PAROXETINE; QUIPAZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANXIETY DISORDER; ARTICLE; DEPRESSION; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HOMEOSTASIS; HUMAN; IATROGENIC DISEASE; MAJOR DEPRESSION; MOOD DISORDER; MOTOR DYSFUNCTION; NEUROBIOLOGY; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PALLIATIVE THERAPY; PSYCHOSOMATIC DISORDER; REBOUND; RISK ASSESSMENT; SIDE EFFECT; SLEEP DISORDER; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE ATTEMPT; SYMPTOMATOLOGY; WEIGHT GAIN; WITHDRAWAL SYNDROME;

ANTIDEPRESSIVE AGENTS; HOMEOPATHY; HUMANS; SEROTONIN; SUBSTANCE WITHDRAWAL SYNDROME; SUICIDE;

EID: 63549113234     PISSN: 14754916     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.homp.2009.02.004     Document Type: Article

References (40)

1. Hahnemann S. Essay on a new principle for ascertaining the curative power of drugs, and some examinations of the previous principles. Hufeland's J 2 (1796) 391
2. Hahnemann S. Organon of medicine. 6th edn. [Boericke W, Trans.] (1991), B Jain Publishers, New Delhi
3. Mittelstaedt P., and Weingartner P. Laws of nature. [Are the laws of logic laws of nature?, Part I, pages 27-47] (2005), Springer, Heidelberg
4. Teixeira M.Z. Semelhante cura semelhante: o princípio de cura homeopático fundamentado pela racionalidade médica e científica (Similar cures similar: the homeopathic cure principle based by the medical and scientific rationality) (1998), Editorial Petrus, São Paulo
5. Teixeira M.Z. Similitude in modern pharmacology. Homeopathy 88 3 (1999) 112-120
6. Teixeira M.Z. Homeopathic use of modern medicines: utilisation of the curative rebound effect. Med Hypotheses 60 2 (2003) 276-283
7. Teixeira M.Z. 'Paradoxical strategy for treating chronic diseases': a therapeutic model used in homeopathy for more than two centuries. Homeopathy 94 4 (2005) 265-266
8. Teixeira M.Z. Evidence of the principle of similitude in modern fatal iatrogenic events. Homeopathy 95 4 (2006) 229-236
9. Teixeira M.Z. NSAIDs, myocardial infarction, rebound effect and similitude. Homeopathy 96 1 (2007) 67-68
10. Teixeira M.Z. Bronchodilators, fatal asthma, rebound effect and similitude. Homeopathy 96 2 (2007) 135-137
11. Hodding G.C., Jann M., and Ackerman I.P. Drug withdrawal syndromes - a literature review. West J Med 133 (1980) 383-391
12. Wolfe R.M. Antidepressant withdrawal reactions. Am Fam Physician 56 2 (1997) 455-462
13. Oniani T.N., and Akhvlediani G.R. Influence of some monoamine oxidase inhibitors on the sleep-wakefulness cycle of the cat. Neurosci Behav Physiol 18 4 (1988) 301-306
14. Kupfer D.J., Pollock B.G., Perel J.M., Miewald J.M., Grochocinski V.J., and Ehlers C.L. Effect of pulse loading with clomipramine on EEG sleep. Psychiatry Res 54 2 (1994) 161-175
15. Smith R.L., Barrett R.J., and Sanders-Bush E. Neurochemical and behavioral evidence that quipazine-ketanserin discrimination is mediated by serotonin2A receptor. J Pharmacol Exp Ther 275 2 (1995) 1050-1057
16. Borrelli B., Spring B., Niaura R., Kristeller J., Ockene J.K., and Keuthen N.J. Weight suppression and weight rebound in ex-smokers treated with fluoxetine. J Consult Clin Psychol 67 1 (1999) 124-131
17. Pace-Schott E.F., Gersh T., Silvestri R., Stickgold R., Salzman C., and Hobson J.A. SSRI treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjects. J Sleep Res 10 2 (2001) 129-142
18. D'Aquila P.S., Panin F., and Serra G. Long-term imipramine withdrawal induces a depressive-like behaviour in the forced swimming test. Eur J Pharmacol 492 1 (2004) 61-63
19. Lerman C., Niaura R., Collins B.N., et al. Effect of bupropion on depression symptoms in a smoking cessation clinical trial. Psychol Addict Behav 18 4 (2004) 362-366
20. Huang X.F., Han M., Huang X., Zavitsanou K., and Deng C. Olanzapine differentially affects 5-HT2A and 2C receptor mRNA expression in the rat brain. Behav Brain Res 171 2 (2006) 355-362
21. Lader M. Pharmacotherapy of mood disorders and treatment discontinuation. Drugs 67 12 (2007) 1657-1663
22. Schatzberg A., Haddad P., Kaplan E., et al. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. J Clin Psychiatry 58 Suppl. 7 (1997) 5-10
23. Tamam L., and Ozpoyraz N. Selective serotonin reuptake inhibitor discontinuation syndrome: a review. Adv Ther 19 1 (2002) 17-26
24. Price J., Waller P., Wood S., and MacKay A.V. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 42 6 (1996) 757-763
25. Haddad P., Anderson I., and Rosenbaum J.F. Antidepressant discontinuation syndromes. In: Haddad P., Dursun S., and Deakin B. (Eds). Adverse Syndromes and Psychiatric Drugs (2004), Oxford University Press, Oxford 184-205
26. Weller I. Report of the committee on safety of medicines expert working group on the safety of selective serotonin reuptake inhibitor antidepressants (2005), London Stationery Office, London
27. Rosenbaum J.F., Fava M., Hoog S.L., Ascroft R.C., and Krebs W.B. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomised clinical trial. Biol Psychiatry 44 2 (1998) 77-87
28. Hindmarch I., Kimber S., and Cockle S. Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol 15 6 (2000) 305-318
29. Judge R., Parry M., Quail D., and Jacobson J.G. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol 17 5 (2002) 217-225
30. Zajecka J., Fawcett J., Amsterdam J., et al. Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study. J Clin Psychopharmacol 18 3 (1998) 193-197
31. Baldwin D., Montgomery S.A., Nil R., and Lader M. Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 10 1 (2007) 73-84
32. Harvey B.H., Retief R., Korff A., and Wegener G. Increased hippocampal nitric oxide synthase activity and stress responsiveness after imipramine discontinuation: role of 5HT 2A/C-receptors. Metab Brain Dis 21 2-3 (2006) 211-220
33. Coupland N.J., Bell C.J., and Potokar J.P. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 16 5 (1996) 356-362
34. Hammad T.A., Laughren T., and Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63 3 (2006) 332-339
35. March J., Silva S., Petrycki S., et al. Treatment for adolescents with depression study team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA 292 7 (2004) 807-820
36. Bridge J.A., Iyengar S., Salary C.B., et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 297 15 (2007) 1683-1696
37. Baldessarini R.J., Pompili M., and Tondo L. Suicidal risk in antidepressant drug trials. Arch Gen Psychiatry 63 3 (2006) 246-248
38. Dopheide J.A. Recognizing and treating depression in children and adolescents. Am J Health Syst Pharm 63 3 (2006) 233-243
39. U.S. Food and Drug Administration. FDA Public Health Advisory (May 2, 2007): "FDA proposes new warnings about suicidal thinking, behavior in young adults who take antidepressant medications". Available from:. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01624.html
40. Vaswani M., Linda F.K., and Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 27 1 (2003) 85-102